Compare JBL & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBL | DGX |
|---|---|---|
| Founded | 1966 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 20.5B |
| IPO Year | 1993 | 1996 |
| Metric | JBL | DGX |
|---|---|---|
| Price | $235.84 | $186.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $246.50 | $196.69 |
| AVG Volume (30 Days) | ★ 1.1M | 997.7K |
| Earning Date | 03-19-2026 | 02-10-2026 |
| Dividend Yield | 0.13% | ★ 1.71% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 6.42 | ★ 8.51 |
| Revenue | ★ $31,113,000,000.00 | $10,850,000,000.00 |
| Revenue This Year | $10.53 | $12.37 |
| Revenue Next Year | $7.84 | $3.54 |
| P/E Ratio | $36.97 | ★ $21.97 |
| Revenue Growth | 13.18 | ★ 13.74 |
| 52 Week Low | $108.66 | $153.99 |
| 52 Week High | $258.05 | $197.55 |
| Indicator | JBL | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 58.77 |
| Support Level | $239.00 | $179.73 |
| Resistance Level | $247.13 | $184.39 |
| Average True Range (ATR) | 9.15 | 3.58 |
| MACD | -0.99 | 0.24 |
| Stochastic Oscillator | 40.53 | 75.40 |
Jabil Inc. is a U.S based company providing engineering, manufacturing, and supply chain solutions. It provides comprehensive electronics design, production, and product management services to companies in various industries and end markets. It operates through three segments: Regulated Industries, serving automotive, healthcare, and renewables; Intelligent Infrastructure, focused on AI, cloud, data centers, and communications, driving the majority of revenue; and Connected Living and Digital Commerce, specializing in digitalization and automation, such as robotics and warehouse automation. The company operates in the U.S., Mexico, China, Malaysia, Singapore, and several other markets.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.